NCT00143208 - Evaluation Of Intraocular Pressure Lowering-Effect Of Xalacom In Patients With Poag Or Oh. | Biotech Hunter

Enrollment

250

Participants

Timeline

Start Date

May 31, 2003

Study Completion Date

April 30, 2006

Conditions

GlaucomaOcular Hypertension

Interventions

DRUG

Xalacom

Trial Locations (21)

10043

Pfizer Investigational Site, Orbassano

20121

Pfizer Investigational Site, Milan

25015

Pfizer Investigational Site, Desenzano (BS)

27100

Pfizer Investigational Site, Pavia

40133

Pfizer Investigational Site, Bologna

44030

Pfizer Investigational Site, Ferrara

52100

Pfizer Investigational Site, Arezzo

57100

Pfizer Investigational Site, Livorno

65100

Pfizer Investigational Site, Pescara

74016

Pfizer Investigational Site, Massafra

74100

Pfizer Investigational Site, Bari

80131

Pfizer Investigational Site, Napoli

81100

Pfizer Investigational Site, Caserta

88100

Pfizer Investigational Site, Catanzaro

90146

Pfizer Investigational Site, Palermo

97100

Pfizer Investigational Site, Ragusa

Unknown

Pfizer Investigational Site, Bollate

Pfizer Investigational Site, Conegliano

00157

Pfizer Investigational Site, Roma

00189

Pfizer Investigational Site, Roma

07100

Pfizer Investigational Site, Sassari

All Listed Sponsors

lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY